Overview
Overview
PEG MGF is a pegylated variant of mechano-growth factor, a muscle-derived IGF-1 splice isoform that is upregulated after mechanical stress or injury[2]. The unique C-terminal E peptide of MGF activates muscle satellite cells and local protein synthesis, initiating tissue repair and growth in addition to IGF-1 receptor signaling[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements. Reconstitute: Add 3.0 mL bac
- Category
- Healing
- Routes
- subcutaneous
Mechanism
PEG MGF
Mechanism of action
Mechanism of action
MGF is a splice variant of IGF-1 that is expressed in muscle tissue following mechanical loading or damage [2] . Unlike systemic IGF-1, MGF acts locally to activate satellite cells and initiate muscle repair processes through its unique C-terminal E peptide domain. Pegylation of MGF extends its half-life, allowing for once-daily subcutaneous administration instead of the frequent local injections required for native MGF. Animal studies have shown that MGF analogues can enhance muscle regeneration, bone healing, and cartilage repair when administered over several weeks.
Key research findings
- 01
(Literature status) No indexed peer-reviewed studies exist on the PEGylated form ("PEG-MGF") itself: a PubMed exact-term search for "PEG-MGF"/"PEGylated MGF"/"PEG MGF" returns zero results. All real preclinical data concern the unmodified MGF C-terminal E-domain peptide (MGF-Ct24E / IGF-1Ec E-peptide), the bioactive moiety; the circulating half-life and dosing figures originate from vendor/wiki pages (and from PEGylation studies of other molecules such as IGF-1), not from peer-reviewed data on this compound.
- 02
(In vitro) The synthetic MGF E-domain peptide was reported to promote proliferation and migration while delaying differentiation of muscle precursor cells and human mesenchymal stem cells, apparently through an IGF-1-receptor-independent mechanism (Mills 2006, PMID 17156777; Collins 2010, PMID 20875825). These are cell-culture observations only.
- 03
(Animal model, mouse) Intramuscular or systemic delivery of the unmodified E-domain peptide was reported to enhance engraftment of transplanted human myogenic precursor cells in immunodeficient mice in a Duchenne muscular dystrophy research context (Mills 2007, PMID 17845560).
- 04
(Animal model, mouse / in vitro) In rodent myocardial infarction models, the E-domain peptide delivered directly (Mavrommatis 2013, PMID 23712705) or via PEG-dimethacrylate hydrogel microstructures (Peña 2015, PMID 25678113) was associated with reduced cardiomyocyte apoptosis and better-preserved contractile function; a later mouse study reported dose-dependent and even opposing effects on cardiac function (Solís 2022, PMID 36467694), indicating the dose-response is not well characterized.
- 05
(Animal model, rabbit / in vitro) In osteoblast cultures and a rabbit radial bone-defect model, MGF-Ct24E was reported to increase osteoblast proliferation via the MAPK-Erk1/2 pathway, initially delay then later promote differentiation, and improve radiographic/histological bone-defect repair at the higher dose tested (Deng 2010, PMID 21057789; Xin 2013, PMID 24033831).
- 06
(Human study) No human study has administered MGF E-domain peptide or PEG-MGF. The only human-related data concern transient up-regulation of endogenous MGF (IGF-1Ec) splice-variant mRNA in skeletal muscle after mechanical loading/resistance exercise — a natural physiological response distinct from administering an exogenous peptide.
Primary source: The research base for PEG-MGF specifically is essentially absent from the peer-reviewed literature: PubMed returns no indexed studies of the PEGylated molecule, and the available evidence concerns the unmodified MGF C-terminal E-domain peptide (MGF-Ct24E), which has a small, early-stage preclinical literature (in vitro cell work plus rodent and rabbit models of muscle, bone, cardiac, and neural repair) from a handful of laboratories. There are no human trials of the administered peptide and no published pharmacokinetic or safety data on the PEGylated form, so maturity is low and confidence remains limited; this is Research Use Only information and not medical advice.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Animal studies demonstrate enhanced muscle, bone, and cartilage regeneration with MGF analogues administered over multiple weeks[4][6].
MGF promotes myogenic precursor cell proliferation and improves muscle repair in models of injury or depletion[6][7].
No human clinical trials have been completed; safety and efficacy in humans remain unestablished.
Protocol Reference
Protocol reference
Commonly cited research range: 200–500 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
200 mcg
Weeks 3–4
300 mcg
Weeks 5–6
400 mcg
Weeks 7–8
500 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 200 mcg | 30 units (0.30 mL) |
| Weeks 3–4 | 300 mcg | 45 units (0.45 mL) |
| Weeks 5–6 | 400 mcg | 60 units (0.60 mL) |
| Weeks 7–8 | 500 mcg | 75 units (0.75 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Pegylation is studied to prolong MGF activity; supporting data are largely preclinical.
The research base for PEG-MGF specifically is essentially absent from the peer-reviewed literature: PubMed returns no indexed studies of the PEGylated molecule, and the available evidence concerns the unmodified MGF C-terminal E-domain peptide (MGF-Ct24E), which has a small, early-stage preclinical literature (in vitro cell work plus rodent and rabbit models of muscle, bone, cardiac, and neural repair) from a handful of laboratories. There are no human trials of the administered peptide and no published pharmacokinetic or safety data on the PEGylated form, so maturity is low and confidence remains limited; this is Research Use Only information and not medical advice.
- 01(Literature status) No indexed peer-reviewed studies exist on the PEGylated form ("PEG-MGF") itself: a PubMed exact-term search for "PEG-MGF"/"PEGylated MGF"/"PEG MGF" returns zero results. All real preclinical data concern the unmodified MGF C-terminal E-domain peptide (MGF-Ct24E / IGF-1Ec E-peptide), the bioactive moiety; the circulating half-life and dosing figures originate from vendor/wiki pages (and from PEGylation studies of other molecules such as IGF-1), not from peer-reviewed data on this compound.
- 02(In vitro) The synthetic MGF E-domain peptide was reported to promote proliferation and migration while delaying differentiation of muscle precursor cells and human mesenchymal stem cells, apparently through an IGF-1-receptor-independent mechanism (Mills 2006, PMID 17156777; Collins 2010, PMID 20875825). These are cell-culture observations only.
- 03(Animal model, mouse) Intramuscular or systemic delivery of the unmodified E-domain peptide was reported to enhance engraftment of transplanted human myogenic precursor cells in immunodeficient mice in a Duchenne muscular dystrophy research context (Mills 2007, PMID 17845560).
- 04(Animal model, mouse / in vitro) In rodent myocardial infarction models, the E-domain peptide delivered directly (Mavrommatis 2013, PMID 23712705) or via PEG-dimethacrylate hydrogel microstructures (Peña 2015, PMID 25678113) was associated with reduced cardiomyocyte apoptosis and better-preserved contractile function; a later mouse study reported dose-dependent and even opposing effects on cardiac function (Solís 2022, PMID 36467694), indicating the dose-response is not well characterized.
- 05(Animal model, rabbit / in vitro) In osteoblast cultures and a rabbit radial bone-defect model, MGF-Ct24E was reported to increase osteoblast proliferation via the MAPK-Erk1/2 pathway, initially delay then later promote differentiation, and improve radiographic/histological bone-defect repair at the higher dose tested (Deng 2010, PMID 21057789; Xin 2013, PMID 24033831).
- 06(Human study) No human study has administered MGF E-domain peptide or PEG-MGF. The only human-related data concern transient up-regulation of endogenous MGF (IGF-1Ec) splice-variant mRNA in skeletal muscle after mechanical loading/resistance exercise — a natural physiological response distinct from administering an exogenous peptide.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to PEG MGF.
- 01Pure Lab Peptides — PEG MGF (2 mg) product page (quality and batch documentation) View Source
- 02Physiological Society — MGF: a local growth factor or a local tissue repair factor? View Source
- 03In Vivo (PubMed) — Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro View Source
- 04International Orthopaedics (PubMed) — Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits View Source
- 05American Journal of Transplantation (PubMed) — A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success View Source
- 06Frontiers in Physiology (PubMed) — Impaired skeletal muscle regeneration induced by macrophage depletion could be partly ameliorated by MGF injection View Source
- 07Cureus — Peptide Therapy (News article on Mechano-Growth Factor) View Source
- 08Rapid Communications in Mass Spectrometry (PubMed) — Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products View Source
- 09CDC — Chapter 6: Vaccine Administration (Epidemiology and Prevention of Vaccine-Preventable Diseases, 14th ed.) View Source
- 10Cleveland Clinic — Lipohypertrophy: Symptoms, Causes, Treatment & Prevention View Source
- 11East Carolina University College of Nursing — Administering Subcutaneous Injections (Clinical Nursing Skills) View Source
- 12Bachem — Handling and Storage Guidelines for Peptides View Source
Observed Effects
Observed effects in cited research
Reported
- Generally well tolerated in preclinical models; mild injection-site reactions may occur with subcutaneous administration.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| PEG MGFthis | A pegylated form of mechano growth factor designed for extended stability and systemic half-life; the C-terminal E-peptide is studied for satellite-cell activation and muscle repair. | subcutaneous | Investigational / RUO |
| PNC-27 | A synthetic peptide combining an HDM-2-binding domain with a membrane-penetrating sequence, studied for selective membrane disruption of cancer cells displaying surface HDM-2. | subcutaneous | Investigational / RUO |
| TB-500 | Upregulates actin, promotes cell migration, reduces inflammation, and stimulates wound healing and tissue repair. | subcutaneous, intramuscular | Investigational / RUO |
| BPC-157 | Promotes angiogenesis, accelerates wound healing, and protects organs. Interacts with growth hormone receptors and NO system. | subcutaneous, intramuscular | Investigational / RUO |
| GHK-Cu | Stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and acts as antioxidant and anti-inflammatory agent. | subcutaneous, topical | Investigational / RUO |
| Pinealon | A synthetic tripeptide bioregulator (Glu-Asp-Arg) studied for cell-penetrating, gene-regulatory activity in neural tissue, with proposed antioxidant and neuroprotective effects. | subcutaneous | Investigational / RUO |
| Prostamax | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro) derived from prostate peptide-complex research, studied for tissue-specific regulatory effects on prostate tissue. | intramuscular | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
No. A PubMed search for "PEG-MGF"/"PEGylated mechano growth factor" returns no indexed studies of the PEGylated molecule itself. The available preclinical research concerns the unmodified MGF C-terminal E-domain peptide (MGF-Ct24E). The extended-half-life and dosing numbers seen on vendor websites are not supported by peer-reviewed data on this compound and should be treated as unverified. This is Research Use Only information, not medical advice.
Mechano growth factor (MGF) is a splice variant of IGF-1 (IGF-1Ec in humans) whose distinct C-terminal "E-domain" can be produced as a short 24-amino-acid synthetic peptide (MGF-Ct24E). "PEG-MGF" refers to that peptide with a polyethylene glycol (PEG) group attached, a chemistry generally intended to slow clearance. Importantly, the biological findings in the literature come from the non-PEGylated peptide; the effect of PEGylation on this specific peptide has not been characterized in indexed studies.
Cell-culture studies report that the peptide can promote proliferation and migration of muscle precursor cells and mesenchymal stem cells while delaying their differentiation, apparently independent of the classical IGF-1 receptor (Mills 2006, PMID 17156777; Collins 2010, PMID 20875825). These are in vitro observations and do not establish any effect in humans.
In rodent and rabbit studies, the unmodified peptide has been investigated in models of muscle-cell transplantation, myocardial infarction, bone-defect repair, and traumatic brain injury, with reports of effects such as improved cell engraftment, reduced cardiomyocyte apoptosis, and enhanced bone-defect repair (e.g., Mills 2007 PMID 17845560; Mavrommatis 2013 PMID 23712705; Deng 2010 PMID 21057789; Liu 2017 PMID 27863093). These are small, early-stage preclinical findings in animals and do not demonstrate safety or efficacy in humans.
No human study has administered MGF E-domain peptide or PEG-MGF. The only human-related data concern endogenous MGF gene expression rising transiently in muscle after resistance exercise or mechanical loading, which is a natural physiological response and is not the same as taking an exogenous peptide.
There is no established human dosing for this compound. The doses that appear in the literature are from animal models (for example, microgram- to milligram-per-kilogram ranges in rodents and rabbits), and research-reported ranges vary; they do not translate to human use. For any protocol-design questions, consult the referenced primary literature and qualified professionals — this is not medical advice.
Peer-reviewed safety, toxicology, and pharmacokinetic data for PEG-MGF in humans are not available. Observed effects in research are limited to the preclinical models described above; notably, one mouse cardiac study reported dose-dependent and even opposing functional effects depending on the dose (Solís 2022, PMID 36467694), underscoring that the dose-response behavior is poorly understood. The absence of reported harms in a few small animal studies should not be interpreted as evidence of human safety.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.